WHO ICTRP trial
CapeOX Study
JPRN-jRCTs051180126 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-jRCTs051180126 |
|---|---|
| Public title | CapeOX Study |
| Scientific title | Phase II study of CapeOX regimen in elderly patients with untreated metastatic gastric cancer - TCOG GI-1601 |
| Primary sponsor | Yamaguchi Kensei |
| Secondary sponsors | Yakult Honsha |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 2 |
| Conditions | gastric cancer |
| Interventions | CapeOX (oxaliplatin; 100 mg/m2 [day 1], capecitabine; 1,500 mg/m2/day [day1-day15]): The treatment will be repeated every 3 weeks, unless the disease progression, unacceptable toxicity, tumor resection, or consent withdrawal |
| Registration date | Mar 18, 2019 |
| Target size | 110 |
| Secondary IDs | UMIN000022450 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: